Loading clinical trials...
Loading clinical trials...
Showing 1-2 of 2 trials
NCT07146906
The purpose of the study is to assess the effect of zigakibart on IgA nephropathy (IgAN) disease progression.
NCT05534919
This is a Phase 3b, multicenter, open-label extension (OLE) study to evaluate the efficacy and safety of Nefecon treatment in Chinese patients who have completed Nef-301 and continue to be treated with a stable dose of Renin-angiotensin system (RAS) inhibitor therapy (Angiotensin-converting enzyme inhibitors (ACEIs) and/or Angiotensin II type I receptor blockers (ARBs).